RT Journal Article
SR Electronic
T1 CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e007398
DO 10.1136/jitc-2023-007398
VO 11
IS 8
A1 Meetze, Kristan
A1 Mehta, Naveen K
A1 Li, Bochong
A1 Findlay, Hannah M
A1 London, Timothy B
A1 Patakas, Agapitos
A1 Michaelson, Jennifer S
A1 Baeuerle, Patrick A
YR 2023
UL http://jitc.bmj.com/content/11/8/e007398.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.